Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes

    ... levels and limited red blood cell transfusion history can predict response to erythropoiesis-stimulating agents ... between endogenous thrombopoietin (THPO) levels and platelet response to romiplostim is unknown. Variables including baseline ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. ASCO Updates Platelet Transfusion Guideline Prophylaxis unnecessary for adults undergoing HSCT

    ... stem-cell transplants (HSCT) may safely delay platelet infusion until the first sign of bleeding, as opposed to ... infusion, according to an updated guideline for platelet transfusion in patients with cancer. The recommendation, which applies ...

    Research Article last updated 12/06/2017 - 11:23am.

  3. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes

    ... System and only those low/intermediate-1 patients with transfusion-dependent anemia or platelet counts <50 × 109 /L or a significant clinical hemorrhage ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.

    ... this approach. Patients may require frequent blood and platelet transfusion support which is expensive and inconvenient. Life-threatening ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Therapy for aplastic anemia

    ... registry, including cord blood. He is red cell- and platelet transfusion -dependent. He has been recommended therapy with ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Eltrombopag and improved hematopoiesis in refractory aplastic anemia

    ... were clinically significant changes in blood counts or transfusion independence . Patients with a response continued to receive ... minimal toxic effects. Nine patients no longer needed platelet transfusions (median increase in platelet count, 44,000 per cubic ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... or partial remission, red blood cell [RBC] or platelet transfusion independence [TI], or hematologic improvement, (IWG 2006) was ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

    ... complete remission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously treated patients and 73% in ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria

    ... Three of 4 patients had an improvement in their platelet count, and 3 of 3 had major improvement in abdominal ... with an increase in hemoglobin level and decreased transfusion requirement. CONCLUSIONS: These data indicate that SSAE ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Cotransplantation of allogeneic mesenchymal and hematopoietic stem cells in children with aplastic anemia

    ... × 10(6)/kg). The mean time for neutrophil and platelet recovery was 12.3 and 13.8 days, respectively. Acute GvHD grade I ... no chronic GvHD was documented. All patients were alive and transfusion independent at a median follow-up of 15 months (range: 6-29 ...

    Research Article last updated 07/20/2018 - 5:14pm.